Thomas Gad Sells 4,000 Shares of Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) Chairman Thomas Gad sold 4,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $32.48, for a total transaction of $129,920.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Thomas Gad also recently made the following trade(s):

  • On Monday, November 18th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $28.85, for a total transaction of $115,400.00.
  • On Monday, November 4th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $30.01, for a total transaction of $120,040.00.
  • On Friday, October 18th, Thomas Gad sold 7,250 shares of Y-mAbs Therapeutics stock. The stock was sold at an average price of $16.71, for a total transaction of $121,147.50.
  • On Monday, October 21st, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $31.65, for a total transaction of $126,600.00.
  • On Monday, October 7th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $25.21, for a total transaction of $100,840.00.
  • On Monday, September 16th, Thomas Gad sold 4,000 shares of Y-mAbs Therapeutics stock. The shares were sold at an average price of $30.59, for a total transaction of $122,360.00.

Y-mAbs Therapeutics stock traded up $1.16 during mid-day trading on Wednesday, reaching $33.78. The company had a trading volume of 177,318 shares, compared to its average volume of 150,686. Y-mAbs Therapeutics, Inc has a 1 year low of $15.17 and a 1 year high of $34.19. The company has a debt-to-equity ratio of 0.02, a current ratio of 7.12 and a quick ratio of 7.12. The company has a market capitalization of $1.34 billion, a P/E ratio of -22.52 and a beta of 1.22. The stock’s 50-day simple moving average is $29.47 and its 200-day simple moving average is $25.57.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Wednesday, November 13th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.54) by ($0.16). On average, equities analysts forecast that Y-mAbs Therapeutics, Inc will post -2.33 EPS for the current fiscal year.

A number of brokerages have issued reports on YMAB. Guggenheim began coverage on shares of Y-mAbs Therapeutics in a report on Wednesday, November 27th. They issued a “buy” rating and a $40.00 target price for the company. Cowen reaffirmed a “buy” rating on shares of Y-mAbs Therapeutics in a report on Monday, October 28th. Wedbush began coverage on shares of Y-mAbs Therapeutics in a report on Tuesday, September 3rd. They issued an “outperform” rating and a $38.00 target price for the company. Zacks Investment Research cut shares of Y-mAbs Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Finally, ValuEngine raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 1st. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $38.00.

Several hedge funds have recently added to or reduced their stakes in YMAB. Bank of Montreal Can acquired a new stake in shares of Y-mAbs Therapeutics in the second quarter valued at approximately $39,000. Metropolitan Life Insurance Co NY acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $190,000. California Public Employees Retirement System acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $254,000. Swiss National Bank acquired a new stake in shares of Y-mAbs Therapeutics in the second quarter valued at approximately $290,000. Finally, Tuttle Tactical Management acquired a new stake in shares of Y-mAbs Therapeutics in the third quarter valued at approximately $309,000. Institutional investors and hedge funds own 33.08% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.

Featured Article: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for Y-mAbs Therapeutics (NASDAQ:YMAB)

Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.